Compare · FMS vs MGRX
FMS vs MGRX
Side-by-side comparison of Fresenius Medical Care AG (FMS) and Mangoceuticals Inc. (MGRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FMS and MGRX operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $13.13B, about 1570.9x MGRX ($8.4M).
- MGRX has been more active in the news (12 items in the past 4 weeks vs 7 for FMS).
- FMS has more recent analyst coverage (23 ratings vs 0 for MGRX).
- Company
- Fresenius Medical Care AG
- Mangoceuticals Inc.
- Price
- -
- -
- Market cap
- $13.13B
- $8.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 7
- 12
- Recent ratings
- 23
- 0
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest FMS
- Amendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery
- Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda
- Fresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patients
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical downgraded by BNP Paribas Exane with a new price target
Latest MGRX
- Mangoceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 10-Q filed by Mangoceuticals Inc.
- SEC Form 425 filed by Mangoceuticals Inc.
- Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
- Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
- Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
- Mangoceuticals’ Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
- Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development
- Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
- SEC Form 425 filed by Mangoceuticals Inc.